Tuesday, 19 Mar 2019

You are here

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

The COAST-V trial was a phase 3, randomised, double-blind, placebo-controlled superiority study of ixekizumab, adult patients with inadequate response or intolerance to non-steroidal anti-inflammatory drugs.

Patients (n=341) were randomly assigned (1:1:1:1) to 80 mg subcutaneous ixekizumab every two (Q2W) or four (Q4W) weeks, 40 mg adalimumab Q2W (active reference group), or placebo (16%). The primary endpoint was the ASAS40 response at week 16.

ASAS40 responses were higher with ixekizumab Q2W (52%; p<0·0001), ixekizumab Q4W (48%; p<0·0001) than that seen with adalimumab (36%) or placebo.  Adalimumab results were also significantly better than placebo responses.

MRI assessment of the spine and SI joints showed adalimumab and both doses of ixekizumab to be signficantly less SPARCC score changes from baseline assessments.

Serious infections were seen in 1% and there was one Candida infection in the adalimumab group.

IL-17A inhibition appears to be a safe and effective treatment option for patients with AxSpA and ankylosing spondylitis. 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed. 

AAD/NPF Guidelines on Biologic Use in Psoriasis

Menter and colleagues from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) have published their expert consensus guidelines for the use of biologics in psoriasis.

Dermatology Guidelines for Psoriatic Comorbidities

The JAAD has published joint guidelines from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) on the approach, management and dermatolgist roles for select comorbid conditions. 

Early TNF inhibition in Early Psoriatic Arthritis

A small, double-blind, randomised, placebo-controlled trial in early psoriatic arthritis (PsA) has shown that first-line use of golimumab and methotrexate (MTX) is superior to MTX alone in inducing remission in PsA.